Frazier Life Sciences Management, L.P. Elevation Oncology, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.7 Billion
- Q2 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in Elevation Oncology, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 2,958,579 shares of ELEV stock, worth $1.8 Million. This represents 0.47% of its overall portfolio holdings.
Number of Shares
2,958,579Holding current value
$1.8 Million% of portfolio
0.47%Shares
1 transactions
Others Institutions Holding ELEV
# of Institutions
81Shares Held
52MCall Options Held
700Put Options Held
2.1K-
Logos Global Management LP San Francisco, CA3.85MShares$2.35 Million0.98% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.6MShares$2.2 Million0.05% of portfolio
-
Tang Capital Management LLC San Diego, CA3.06MShares$1.87 Million1.01% of portfolio
-
Aisling Capital Management LP New York, NY2.83MShares$1.73 Million3.35% of portfolio
-
Black Rock Inc. New York, NY2.49MShares$1.52 Million0.0% of portfolio
About Elevation Oncology, Inc.
- Ticker ELEV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 23,300,900
- Market Cap $14.2M
- Description
- Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...